Table 1.
Summary of Demographic and Baseline Characteristics by Baseline Quartile Groups of IL‐6 and hs‐CRP
| Characteristics | IL‐6 | hs‐CRP | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| <1.4 ng/L (n=3148) | 1.4–2.1 ng/L (n=3952) | 2.1–3.2 ng/L (n=3742) | ≥3.2 ng/L (n=3769) | P Value | <0.6 mg/L (n=2872) | 0.6–1.3 mg/L (n=3987) | 1.3–3.1 mg/L (n=3864) | ≥3.1 mg/L (n=3683) | P Value | |
| Age at randomization, y | 62.8 (9.2) | 64.2 (9.1) | 64.8 (9.3) | 65.8 (9.5) | <0.0001 | 64.8 (9.0) | 64.8 (9.2) | 64.3 (9.4) | 63.8 (9.5) | <0.0001 |
| Male sex, n (%) | 2601 (82.6) | 3284 (83.1) | 3006 (80.3) | 3020 (80.1) | 0.0006 | 2427 (84.5) | 3310 (83.0) | 3161 (81.8) | 2844 (77.2) | <0.0001 |
| Race, n (%) | <0.0001 | <0.0001 | ||||||||
| White | 2326 (73.9) | 3231 (81.8) | 3129 (83.6) | 3107 (82.4) | 1924 (67.0) | 3158 (79.2) | 3201 (82.8) | 3065 (83.2) | ||
| Black | 38 (1.2) | 85 (2.2) | 80 (2.1) | 113 (3.0) | 32 (1.1) | 62 (1.6) | 72 (1.9) | 138 (3.7) | ||
| Central/South/South East Asian | 253 (8.0) | 253 (6.4) | 263 (7.0) | 288 (7.6) | 263 (9.2) | 264 (6.6) | 250 (6.5) | 215 (5.8) | ||
| East Asian/Japanese | 470 (14.9) | 286 (7.2) | 206 (5.5) | 178 (4.7) | 602 (21.0) | 408 (10.2) | 256 (6.6) | 192 (5.2) | ||
| Other | 61 (1.9) | 97 (2.5) | 64 (1.7) | 83 (2.2) | 51 (1.8) | 95 (2.4) | 85 (2.2) | 73 (2.0) | ||
| Geographic region, n (%) | <0.0001 | <0.0001 | ||||||||
| Asia/Pacific | 818 (26.0) | 645 (16.3) | 580 (15.5) | 538 (14.3) | 943 (32.8) | 800 (20.1) | 615 (15.9) | 478 (13.0) | ||
| Eastern Europe | 668 (21.2) | 979 (24.8) | 953 (25.5) | 850 (22.6) | 469 (16.3) | 865 (21.7) | 1003 (26.0) | 1006 (27.3) | ||
| North America | 709 (22.5) | 1050 (26.6) | 998 (26.7) | 1082 (28.7) | 669 (23.3) | 1069 (26.8) | 977 (25.3) | 1046 (28.4) | ||
| South America | 113 (3.6) | 208 (5.3) | 240 (6.4) | 314 (8.3) | 127 (4.4) | 229 (5.7) | 220 (5.7) | 232 (6.3) | ||
| Western Europe | 840 (26.7) | 1070 (27.1) | 971 (25.9) | 985 (26.1) | 664 (23.1) | 1024 (25.7) | 1049 (27.1) | 921 (25.0) | ||
| BMI, kg/m2 | 27.5 (4.1) | 28.8 (4.6) | 29.7 (5.1) | 30.0 (5.7) | <0.0001 | 27.0 (4.2) | 28.5 (4.5) | 29.5 (4.9) | 30.5 (5.6) | <0.0001 |
| Weight, kg | 79.5 (15.3) | 83.7 (16.4) | 85.9 (17.5) | 86.6 (19.6) | <0.0001 | 78.1 (15.5) | 82.5 (15.9) | 85.8 (17.7) | 88.0 (19.0) | <0.0001 |
| Current smoker, n (%) | 490 (15.6) | 673 (17.0) | 696 (18.6) | 794 (21.1) | <0.0001 | 407 (14.2) | 600 (15.0) | 754 (19.5) | 857 (23.3) | <0.0001 |
| Hypertension, n (%) | 2066 (65.6) | 2806 (71.0) | 2742 (73.3) | 2838 (75.3) | <0.0001 | 1904 (66.3) | 2749 (68.9) | 2799 (72.4) | 2813 (76.4) | <0.0001 |
| Diabetes mellitus, n (%) | 1032 (32.8) | 1470 (37.2) | 1483 (39.6) | 1666 (44.2) | <0.0001 | 1014 (35.3) | 1444 (36.2) | 1451 (37.6) | 1640 (44.5) | <0.0001 |
| Renal dysfunction, n (%) | 632 (20.1) | 1046 (26.5) | 1220 (32.6) | 1505 (39.9) | <0.0001 | 688 (24.0) | 1094 (27.4) | 1198 (31.0) | 1354 (36.8) | <0.0001 |
| Prior MI, n (%) | 1823 (57.9) | 2376 (60.1) | 2243 (59.9) | 2209 (58.6) | 0.1752 | 1649 (57.4) | 2309 (57.9) | 2280 (59.0) | 2180 (59.2) | 0.3826 |
| Multivessel CHD, n (%) | 392 (12.5) | 545 (13.8) | 533 (14.2) | 604 (16.0) | 0.0003 | 363 (12.6) | 537 (13.5) | 527 (13.6) | 565 (15.3) | 0.0116 |
| Polyvascular disease, n (%) | 309 (9.8) | 559 (14.1) | 645 (17.2) | 712 (18.9) | <0.0001 | 313 (10.9) | 524 (13.1) | 619 (16.0) | 723 (19.6) | <0.0001 |
| Prior PCI/CABG surgery, n (%) | 2386 (75.8) | 2969 (75.1) | 2787 (74.5) | 2752 (73.0) | 0.0472 | 2205 (76.8) | 3042 (76.3) | 2835 (73.4) | 2702 (73.4) | 0.0003 |
| Systolic BP, mm Hg | 130.6 (15.8) | 132.1 (16.1) | 132.2 (16.5) | 131.7 (17.2) | <0.0001 | 130.4 (16.0) | 131.8 (16.2) | 132.2 (16.5) | 132.0 (16.8) | <0.0001 |
| Diastolic BP, mm Hg | 78.8 (10.0) | 79.0 (10.2) | 79.0 (10.3) | 77.9 (10.7) | <0.0001 | 77.6 (10.1) | 78.8 (10.3) | 79.3 (10.3) | 79.1 (10.4) | <0.0001 |
| hs‐CRP, mg/L | 1.1 (1.7) | 1.6 (1.9) | 2.7 (3.3) | 6.5 (11.7) | <0.0001 | |||||
| cTnT‐hs, ng/L | 9.1 (6.8) | 11.3 (13.1) | 12.6 (16.2) | 16.3 (25.2) | <0.0001 | 10.4 (8.2) | 11.5 (9.9) | 12.5 (17.3) | 14.8 (28.1) | <0.0001 |
| NT‐proBNP, ng/L | 217.8 (311.1) | 284.5 (409.1) | 350.9 (495.5) | 604.0 (1344.4) | <0.0001 | 285.3 (506.5) | 307.2 (526.3) | 362.3 (701.5) | 525.9 (1228.9) | <0.0001 |
| Cystatin C, mg/L | 1.0 (0.2) | 1.0 (0.2) | 1.1 (0.3) | 1.2 (0.4) | <0.0001 | 1.0 (0.3) | 1.0 (0.3) | 1.1 (0.3) | 1.1 (0.3) | <0.0001 |
| GDF‐15, ng/L | 1248 (819) | 1433 (948) | 1586 (1022) | 1958 (1549) | <0.0001 | 1433.2 (974.3) | 1477.2 (1059.2) | 1543.9 (1085.7) | 1794.2 (1382.8) | <0.0001 |
| Lp‐PLA2 activity, μmol/min per L | 169.5 (46.9) | 175.5 (46.9) | 177.1 (47.6) | 180.0 (49.3) | <0.0001 | 167.6 (47.6) | 173.4 (45.4) | 179.9 (47.6) | 180.8 (49.8) | <0.0001 |
BMI indicates body mass index; BP, blood pressure; CABG, coronary artery bypass graft; CHD, coronary heart disease; cTnT‐hs, high‐sensitivity cardiac troponin‐T; GDF‐15, growth differentiation factor 15; hs‐CRP, high‐sensitivity C‐reactive protein; IL‐6, interleukin‐6; Lp‐PLA2, lipoprotein‐associated phospholipase A2; MI, myocardial infarction; NT‐proBNP, N‐terminal pro B‐type natriuretic peptide; and PCI, percutaneous coronary intervention.